JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic risk factors and the role of systemic inflammatory response index in predicting outcomes for non-muscle-invasive bladder cancer

  • 0Department of Urology, Zhumadian Central Hospital Affiliated to Huanghuai University, Zhumadian, Henan, China.
Frontiers in Oncology +

|

October 6, 2025

|

October 6, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

The systemic inflammatory response index (SIRI) predicts non-muscle-invasive bladder cancer (NMIBC) progression but not recurrence. Combining SIRI with traditional factors improves risk stratification for personalized NMIBC management.

Area Of Science

  • Oncology
  • Urology
  • Inflammation Biomarkers

Background

  • Non-muscle-invasive bladder cancer (NMIBC) has variable prognosis and recurrence/progression risks.
  • Traditional clinicopathological factors offer limited prognostic accuracy for NMIBC.
  • Novel biomarkers are needed for improved NMIBC risk stratification.

Purpose Of The Study

  • To evaluate the prognostic role of the systemic inflammatory response index (SIRI).
  • To assess SIRI's ability to predict outcomes in NMIBC patients.
  • To compare SIRI with traditional risk factors for NMIBC prognosis.

Main Methods

  • Retrospective analysis of 158 NMIBC patients undergoing transurethral resection of bladder tumor (TURBT).
  • Stratification into recurrence/non-recurrence and progression/non-progression groups.
  • Receiver operating characteristic (ROC) analysis for SIRI cutoff, Kaplan-Meier survival, and Cox regression for progression-free survival (PFS).

Main Results

  • Optimal SIRI cutoff for progression prediction was 0.716 (AUC=0.689).
  • High SIRI (≥0.716) correlated with significantly higher progression risk and poorer PFS.
  • Multivariate analysis identified high SIRI, tumor count, and primary diagnosis as independent predictors of PFS. High SIRI also increased recurrence rates in Ta and T1 subgroups.

Conclusions

  • SIRI is a significant predictor of NMIBC progression, but not recurrence-free survival (RFS).
  • Integrating SIRI with clinicopathological factors enhances risk stratification for NMIBC.
  • SIRI aids in personalized management strategies for NMIBC patients.

Keywords: